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Abstract 
Background. Heparin binding protein (HBP) is released from neutrophilic secretory vesicles upon neutrophil 
adhesion on the endothelium. HBP mediates capillary hyperpermeability experimentally. In sepsis, HBP 
predicts organ dysfunction. Cardiopulmonary bypass induces both neutrophil activation and 
hyperpermeability. We hypothesized that in cardiopulmonary bypass, HBP is released in the reperfused 
coronary circulation concomitantly with neutrophil adhesion. 
Methods. In 30 patients undergoing aortic valve replacement, concomitant blood samples were drawn from 
the coronary sinus and arterial line before aortic crossclamping and 5 min after reperfusion to calculate 
transcoronary differences. Plasma HBP concentrations, neutrophil markers lactoferrin and myeloperoxidase, 
myocardial injury marker heart-type fatty acid binding protein (hFABP) and leukocyte differential counts 
were measured. 
Results. Arterial HBP was 4.1 (3.6–5.3) ng/ml preoperatively and 150.0 (108.2–188.6) ng/ml after aortic 
declamping. HBP increased 39-fold, lactoferrin 16-fold and myeloperoxidase 4-fold during cardiopulmonary 
bypass. Before cardiopulmonary bypass, there were marginal transcoronary differences in HBP [1.4 (-0.4–
3.6) ng/ml, p=0.001] and hFABP [0.4 (-0.04–3.5) ng/ml, p=0.001] but not in the other parameters. During 
reperfusion, transcoronary HBP release [6.4 (1.8–13.7) ng/ml, p<0.001] was observed, concomitantly with 
transcoronary neutrophil sequestration [-0.14 (-0.28–0.01) x10^9/l, p=0.001] and transcoronary hFABP 
release [6.9 (3.0–25.8) ng/ml, p<0.001]. There were no transcoronary differences in lactoferrin or 
myeloperoxidase during reperfusion. 
Conclusions. CPB results in substantial increase in circulating HBP. HBP is also released from the 
reperfused coronary circulation, concomitantly with coronary neutrophil adhesion and myocardial injury. 
HBP may be one candidate for a humoral factor mediating capillary leak in cardiopulmonary bypass. 
 
Abstract word count: 248 
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Heparin binding protein (HBP) is a 37-kD granule protein of neutrophils. In neutrophils, it is located both in 
the secretory vesicles and the azurophilic granules [1]. This dual localization makes HBP an interesting 
biomarker for neutrophil activation. Because azurophilic granules show the lowest propensity to be 
exocytosed, HBP stored in these granules is mainly released in the tissues after extravasation. Secretory 
vesicles, on the contrary, are mobilized first [2]. This results in rapid increase in plasma HPB concentrations. 
As a sensitive indicator of intravascular neutrophil activation, HBP has gained increasing interest as a 
promising inflammatory biomarker during the recent years. High HBP is associated with severe sepsis and 
septic shock [3]. Importantly, HBP performs well in predicting meaningful clinical outcomes. Among septic 
patients, it predicts development of organ dysfunction in general [4] as well as more specifically circulatory 
failure [5, 6], respiratory failure [6, 7] and acute kidney injury [8, 9]. After cardiac arrest, HBP 
concentrations predict death [10].  
 
Neutrophils are activated upon adhesion to endothelial cells. During firm adhesion, coupling of β2-integrins 
on neutrophil plasma membrane triggers release of HBP [11]. Intraluminally released HBP binds to 
glycosaminoglycans on the endothelium [12, 13]. HBP is proposed to have an important role in capillary 
leak. It induces endothelial hyperpermeability in vitro [11, 14]. In experimental conditions in vivo, 
intravenous administration of HBP induces acute lung injury with histological features similar to those after 
lipopolysaccharide administration [14]. Finally, in patients with septic shock, plasma HBP concentrations are 
associated with fluid overload and the degree of hypoxemia [14]. Like sepsis, also cardiopulmonary bypass 
(CPB) is associated with hyperpermeability [15, 16]. 
 
There is substantial amount of data demonstrating pathophysiological significance of activated neutrophils in 
experimental cardiac ischemia-reperfusion injury [17]. Although CPB is classically known to result in strong 
neutrophil activation, coronary neutrophil sequestration after aortic declamping has not been associated with 
concomitant transcoronary neutrophil activation in cardiac surgical patients [18]. Probably intracoronary 
neutrophil activation upon endothelial adhesion has been beyond the detection limit of available laboratory 
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methods. HBP has not been investigated in cardiac surgery. The hypothesis of the present study was two-
fold. First, we hypothesized that CPB will induce more pronounced increase in HBP than in classical 
markers of neutrophil specific granules (lactoferrin, LF) and azurophilic granules (myeloperoxidase, MPO) 
[19]. Second, we hypothesized that HBP is sensitive enough to detect intracoronary neutrophil activation 
during reperfusion after aortic declamping in patients without coronary artery disease undergoing aortic 
valve reconstruction. 
 
Patients and Methods 
The study was approved by the Ethics Committee of Helsinki University Hospital. Written informed consent 
was obtained from all patients before the enrolment in the study. Thirty patients undergoing aortic valve 
replacement surgery (AVR) due to aortic valve stenosis were prospectively recruited. Exclusion criteria were 
as follows: coronary artery disease, left ventricular ejection fraction < 30%, systemic glucocorticoid 
medication or need for perioperative glucocorticoid substitution, immunosuppressive medication, other 
cardiac surgery than AVR in the same session, atrial fibrillation, insufficient cessation of antiplatelet and 
anticoagulation therapy (clopidogrel or ticagrelor < 5 days, low molecular weight heparins < 2 days). 
Anesthesia was induced with etomidate, alfentanil and rocuronium and maintained with sevoflurane, 
alfentanil infusion and rocuronium boluses. Pulmonary artery catheter was placed after the induction of 
anesthesia.  
 
Affinity NT (Medronic International Trading Sàrl, Tolochenaz, Switzerland) oxygenator and Trillium 
(Medronic International Trading Sàrl, Tolochenaz, Switzerland) tubing were used. Patients received 300 
IU/kg of heparin and additional boluses to achieve activated clotting time > 480 s. The aorta and right atrium 
were cannulated. The coronary sinus was cannulated with a 14Fr balloon tipped Retrograde Cardioplegia 
Catheter (Edwards Lifesciences, Irvine, CA, USA). The initial volume of the antegrade cold blood 
cardioplegia solution (4:1 cardioplegia solution to blood ratio) was double the volume needed for cessation 
of all cardiac electrical activity but never less than 1000 ml. Cardiac arrest was maintained by retrograde 
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infusion of 300 ml of blood cardioplegia solution (8:1 cardioplegia solution to blood ratio) every 20 minutes. 
Stöckert S5 roller pump (Sorin Group Deutschland Gmbh, Munich, Germany) was used for CPB, flow 
adjusted to 2.4 l/min x body surface area, mixed venous oxygen saturation maintained over 70%, fraction of 
inspired oxygen at 70%, partial pressure of carbon dioxide within 4.5 – 5-5 kPa and arterial pressure (MAP) 
at 40 – 60 mmHg. Patients were moderately cooled to 33-34 °C.  
 
After weaning from CPB, protamine was administered 0.8-1 mg/100 IU of the initial heparin dose. After 
CPB, MAP of 60 – 80 mmHg was targeted. Hypotension after CPB was treated first by fluid loading 
(Ringers acetate, Albumin 4%) to achieve pulmonary capillary wedge pressure (PCWP) of 12 – 15 mmHg. 
Thereafter, norepinephrine infusion (0.01 – 0.1 µg/kg/min) was commenced if needed. After CPB, cardiac 
index (CI) of > 2.0 L/min/m2 was maintained by pre-load optimization (PCWP 12 – 15 mmHg) as well as 
epinephrine (0.02 – 0.2 µg/kg/min) and milrinone infusion (0.5 µg/kg/min) if needed. Hemoglobin target 
level was < 70g/L during CPB and < 80 g/L off-pump.  
 
In addition to arterial samples, blood samples were obtained from the coronary sinus catheter. Correct 
placement of the catheter was verified with transesophageal ultrasound. In addition, comparisons of partial 
pressure of oxygen (pO2) and oxygen saturation (SO2) between simultaneously taken blood samples from 
the coronary sinus and pulmonary artery (i.e. the mixed venous sample) were made in parallel. Lower pO2 
and lower SO2 in the coronary sinus than in the pulmonary artery was assumed to indicate correct placement 
of the coronary sinus cannula. Blood samples for research were drawn at four time points: (1) before 
induction of anesthesia, “preoperatively”; (2) immediately before ischemia, i.e. immediately before aortic 
cross clamping, “pre-ischemia”; (3) immediately before reperfusion, i.e. immediately before aortic 
declamping, “pre-reperfusion”; (4) 5 min after reperfusion, “reperfusion”. At all time points, 15 ml of arterial 
blood was drawn. At time point 1, the sample was taken from the peripheral arterial cannula. At time points 
2 - 4, blood was drawn from the arterial line of the CPB. At time points 2 and 4, parallel blood samples of 15 
ml were drawn from the coronary sinus into pyrogen free-syringes (BD Plastipak, Madrid, Spain). Samples 
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were immediately divided into two vacuum tubes containing ethylenediaminetetraacetic acid (EDTA, BD 
Vacutainer, Plymouth, UK) and one tube containing sodium citrate (BD Vacutainer, Plymouth, UK). One 
EDTA tube was used for automated leucocyte differential count (Sysmex XE-2100, Sysmex Europe GmbH, 
Norderstedt, Germany). The rest of the tubes were transferred to ice-water bath and plasma was separated 
within 20 min by centrifugation in 2000 g at +4 °C. Plasma was stored in aliquots at -80 °C. Commercial 
enzyme-linked immunosorbent assay (ELISA) kits were used for measurements of HBP (Axis-Shiled 
Diagnostics, Dundee, UK), LF (Hycult Biotech, Uden, The Netherlands), MPO (BioLegend, San Diego, Ca, 
USA) and heart-type fatty acid binding protein (hFABP, Hycult Biotech, Uden, The Netherlands). Since 
hFABP is a rapid and sensitive biomarker of cardiomyocyte injury, it was used as a positive control 
biomarker for detection of transcoronary plasma concentration differences of a parameter [20]. Plasma 
aliquots that were not thawed previously were used for ELISA measurements. Measurements of LF were 
originally conducted for another so far unpublished study and transcoronary difference of LF was not 
available at “pre-ischemia” time point. In addition to ELISA analyses, troponin T (TnT) was measured at the 
clinical laboratory of the hospital exactly at 22 hours and 48 hours after aortic declamping.  
 
Data were analyzed with SPSS 25 for Windows. The study was observational by nature. As there was no 
intervention, power analysis for the size of a treatment group was not applicable. Non-parametric approach 
was used due to small patient number. Friedman’s test was used for testing differences as a function of time. 
Post-hoc, differences between every pair of two consecutive time points (preoperative vs. pre-ischemia; pre-
ischemia vs. pre-reperfusion; pre-reperfusion vs. post-reperfusion) were tested using Wilcoxon signed rank 
test with Bonferroni correction for three comparisons. Likewise, comparison of fold-increase between HBP, 
LF and MPO at a same time point was undertaken with Friedman’s test and Wilcoxon signed rank test as a 
post-hoc test with Bonferroni correction for three comparisons (HBP vs. LF; HBP vs. MPO; LF vs. MPO). 
Wilcoxon signed rank test was also used for comparison of transcoronary differences. Spearman’s test was 
used for bivariate correlations. After Bonferroni correction due to three comparisons, p-values < 0.017 were 
considered statistically significant. Otherwise, p-values < 0.05 were considered significant. Data are 
expressed as median and interquartile range (IQR) or depicted as box-plots.  
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Results 
The study group consisted of fifteen males and fifteen females. The age of the patients was 66 (61-73) years, 
the CPB time 101 (85-114) min and aortic crossclamping time 70 (58-79) min.  
 
Verification of the placement of the coronary sinus catheter 
In the verification of correct placement of the coronary sinus catheter, pO2 and SO2 were higher in the 
coronary sinus sample than in the simultaneously taken mixed venous sample in one patient before CPB (the 
sample was deleted from all analyses). The catheter was readjusted and following samples proved valid pO2 
and SO2 measurements. In all other patients, pO2 and SO2 were lower in the coronary sinus sample than in 
the simultaneously taken mixed venous sample both before CPB and after reperfusion (data not shown). As a 
positive technical control biomarker for the measurement of transcoronary plasma concentration differences, 
hFABP was significantly higher in the coronary sinus samples than in the simultaneously taken arterial 
samples both before CPB [artery: 9.8 (6.0-17.7) ng/ml vs. coronary sinus: 11.2 (6.2-18.3) ng/ml; difference: 
0.4 (-0.04-3.5) ng/ml, p=0.002] and after reperfusion [artery: 36.7 (23.9-59.2) ng/ml vs. coronary sinus: 46.1 
(28.8-90.5) ng/ml; difference: 6.9 (3.0-25.8) ng/ml, p<0.001].  
 
Changes in the arterial samples as a function of time 
Plasma concentrations of HBP, LF and MPO as well as neutrophil count in arterial samples as a function of 
time are presented in the Table 1. All these parameters increased significantly during the study period 
(p<0.001 for all parameters). In HBP, LF and MPO concentrations as well as in neutrophil count, there was a 
significant difference (all p<0.01) in every pair of two consecutive time points (preoperative vs. pre-
ischemia; pre-ischemia vs. pre-reperfusion; pre-reperfusion vs. post-reperfusion). There were significant 
increases also in monocyte and lymphocyte counts in arterial samples during the study period (data not 
shown). For relative comparison between HBP, LF and MPO, granule protein levels at different time points 
are presented as fold-increase, i.e. as multiplies of respective baseline values in the Figure 1. During the 
operation, HBP increased 39-fold, LF 16-fold and MPO 4-fold, compared with the preoperative level.  
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Changes across the coronary circulation 
Before CPB, HBP was marginally but statistically significantly higher in the coronary sinus than in 
simultaneously taken arterial sample (Fig. 2). Transcoronary gradients of neither neutrophil (Fig. 2), 
monocyte (data not shown) nor lymphocyte counts (data not shown) nor MPO concentrations (Fig. 2) were 
observed before CPB. After reperfusion, neutrophil count was significantly lower in the coronary sinus than 
the arterial sample, indicating a transcoronary neutrophil sequestration of -0.14 (-0.28 – 0.01) x10^9/l 
(p=0.001, Fig. 2). After reperfusion, there were also statistically significant entrapment of both monocytes 
[transcoronary difference: -0.06 (-0.11 – 0.02) x10^9/l, p=0.013] and lymphocytes [transcoronary difference: 
-0.020(-0.065 – -0.005) x10^9/l, p=0.021]. After reperfusion, a positive transcoronary HBP concentration 
gradient was observed, indicating transcoronary release of HBP. This transcoronary HBP concentration 
difference did not correlate with transcoronary neutrophil difference, ischemia time or TnT either at 22 hours 
or 48 hours after cardiac reperfusion. Transcoronary concentration gradients of neither LF nor MPO were 
observed before CPB or after reperfusion (Fig. 2). 
 
Comment 
The present results have a three-fold message. First, a substantial increase in plasma concentrations of HBP 
occurs during CPB. Second, in addition to systemic increase, HBP is also released locally in the reperfused 
coronary circulation, concomitantly with coronary neutrophil adhesion. Third, as a biomarker of 
intravascular neutrophil activation, HBP is superior to granule proteins of either specific granules (LF) or 
azurophilic granules (MPO).  
 
The median level of HBP is approximately 30 ng/ml in septic patients without organ dysfunction and 
approximately 50 ng/ml in patients with organ dysfunction. [3, 5]. In our patients undergoing cardiac 
surgery, a median HBP level of 41 ng/ml was reached already before CPB and a median level of 150 ng/ml 
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was observed after reperfusion. In septic patients, plasma HBP concentration higher than 15 ng/ml predicts 
development of organ dysfunction and is associated with four-fold increase in the risk of death [3]. As 
clinical scenario of sepsis is different from that of CPB, direct comparison of septic and cardiac surgical 
patients cannot be done. Still, it can be concluded that substantially high levels of HBP were observed during 
CPB. HBP induces vascular leak in experimental conditions [11, 14]. In septic patients, HBP is correlated 
with the degree of fluid overload and hypoxemia [14]. Plasma obtained from CPB patients mediates 
endothelial hyperpermeability in vitro [16]. Clinical significance of HBP cannot be judged in the present 
observational study of small patient number. Nevertheless, it is tempting to speculate that HBP may be one 
candidate for a humoral mediator of hyperpermeability during CPB [15, 16]. 
 
Numerous experimental studies have shown the pathophysiological significance of activated neutrophils in 
experimental cardiac ischemia-reperfusion injury [17]. Although intracoronary entrapment of neutrophils 
during reperfusion in cardiac surgery has been observed long ago, conclusive evidence of transcoronary 
neutrophil activation has been difficult to obtain [18, 21]. Since also lymphocytes and monocytes are 
sequestrated in the coronary circulation, one may ask if coronary leukocyte entrapment in clinical heart 
surgery is only a passive phenomenon. During cardiac reperfusion at 5 minutes after aortic declamping, we 
observed statistically highly significant release of HBP in the coronary circulation. Median transcoronary 
HBP concentration difference of 6.6 ng/ml was observed and the highest measured difference was 51.6 
ng/ml. As we took simultaneous samples of blood entering and leaving the coronary circulation, the 
transcoronary concentration difference measured momentous production of HBP. The cumulative production 
was likely even more excessive. Furthermore, as HBP is bound to the endothelial glycocalyx, observed 
transcoronary concentration difference probably reflects only a spillover of all HBP released from the 
adhered neutrophils. Taken together, compared with systemic HBP levels in cardiac surgical patients and 
especially in septic patients, intracoronary production of HBP can be regarded strong [3, 5]. Two conclusions 
can be drawn. First, intravascular neutrophil activation in the coronary circulation indeed occurs during 
cardiac reperfusion in clinical heart surgery. Second, this neutrophil activation results in high local 
concentration of HBP in the coronary vascular bed. Again, it can be speculated that accumulating HBP may 
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have significance in coronary endothelial cell injury and myocardial edema formation, occurring both in 
experimental and clinical cardiac surgery [22, 23]. Of note, coronary HPB release was accompanied with the 
coronary release of hFABP that is an early and sensitive biomarker of myocardial injury [20]. 
 
Compared with the preoperative level, HBP increased up to 39-fold after aortic declamping. The 
corresponding increases in LF was 16-fold and that in MPO only 4-fold. Approximately the same 
proportional differences in plasma concentrations of the three granule proteins were observed already at the 
beginning of CPB, i.e. at a moderate level of neutrophil activation. Furthermore, although clear coronary 
release of HBP was observed after cardiac reperfusion, both LF and MPO failed to detect intracoronary 
neutrophil activation. Of note, a marginal but statistically significant transcoronary increase of HBP was 
observed even immediately before aortic crossclamping. Heparinization and initiation of CPB probably 
result in increased circulating HBP concentrations at this early phase of surgery.  However, concomitant 
marginal release of also hFABP was observed. Thus, these two preischemic findings may also reflect subtle 
myocardial and endothelial injury due to cannulation and other surgical manipulation of the heart before 
CPB. These findings further underscore the sensitivity of HBP as a biomarker. The differences between 
neutrophil granule protein concentrations reflect the timing and sequence of neutrophil degranulation during 
physiological neutrophil functions. β2-integrin signaling triggers the release of HBP-containing secretory 
vesicles upon neutrophil adhesion to the endothelium, i.e. in the intravascular space [11]. Azurophilic 
granules (MPO), on the other hand, are important in the formation of a phagosome for killing of microbes in 
the tissues [2]. Specific granules (LF) are somewhere in between. They take part in phagosome formation but 
they also contain β2-integrins that are needed in endothelial adhesion [2]. The fact that secretory vesicles are 
meant to be released intravascularly probably makes HBP a superior neutrophil biomarker in plasma. 
Neutrophilic granule proteins of only either specific or azurophilic granules have been measured in cardiac 
surgery in the past. No clinical impact has been reached in these studies. In future studies, HBP as a 
biomarker may offer a different picture of the clinical significance of neutrophil activation in cardiac 
surgery. 
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The chosen patient population is both a strength and a weakness of the study. Our focus was on the coronary 
reperfusion phenomenon and thus coronary sinus blood samples were obtained. We wanted to avoid the 
confounding effect of coronary artery disease. This reduced, not only the number of patients suitable for the 
study, but also ischemia times and thus variability of ischemic challenge. A small and homogenous patient 
population and fairly subtle ischemic insult may explain the fact that we did not find correlations between 
HBP and clinical indices, i.e. troponin or aortic crossclamping time. On the other hand, both the pre- and 
postischemic coronary HBP release followed the pattern of the coronary hFABP release. While substantial 
coronary release of HBP was observed in patients undergoing isolated AVR, it is likely that coronary 
neutrophil activation would have been even stronger in patients with concomitant coronary pathology and 
longer ischemia times. Thus, the present patient population serves as a meaningful verification of 
reperfusion-induced coronary neutrophil activation in clinical heart surgery. Correct placement of the 
coronary sinus catheter was rigorously verified with multiple methods, i.e. transesophageal cardiac 
ultrasound as well as measuring pO2, SO2 and hFABP. Furthermore, artifact neutrophil activation in vitro 
was reduced to minimum, when blood samples for separation of plasma were immediately cooled on an ice-
water bath and centrifuged at + 4 °C and plasma separated within 20 min.  
 
In conclusion, CPB induced a substantial increase in HBP plasma concentrations in the systemic circulation. 
Furthermore, HBP was also released in the reperfused coronary circulation at the time of coronary neutrophil 
adhesion and myocardial injury. Both experimental in vitro and in vivo evidence has accumulated for the key 
role of HBP in the pathophysiology of capillary leak [11, 14]. According to the present results, HBP is one 
candidate for a humoral factor mediating capillary leak in CPB [16]. In addition, acute kidney injury is a 
frequent complication of CPB. HBP predicts acute kidney injury in septic patients [8, 9]. HBP may perform 
well as a biomarker of organ dysfunction also in cardiac surgery. The clinical significance of HBP needs to 
be verified in a larger patient cohort.  
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Table 1. Arterial values of the parameter during the study period.  
 preop pre-ischemia pre-reperfusion post-reperfusion 
HBP, ng/ml 4.1 (3.6-5.3) 41.0 (34.4.-54.9) 132.7(96.1-198.9) 150.0 (108.2-188.6) 
LF, ng/ml 61.7 (48.4-132.4) 402.8 (310.6-541.1) 975.0 (598.0-1275.3) 1176.5 (653.2-1377.0) 
MPO, ng/ml 58.5 (42.4-75.5) 231.3 (142.2-257.2) 372.1 (273.9-426.2) 411.2 (287.2-465.8) 
neutr, x10^9/l 4.1 (3.1-4.6) 2.4 (1.5-3.6) 5.5 (3.6-8.9) 6.0 (4.4-8.7) 
HBP, heparin binding protein; IQR, interquartile range; LF, lactoferrin; MPO, myeloperoxidase; neutr, 
neutrophil count. All parameters increased significantly during the study period (all p<0.001). 
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Figure legends 
 
Figure 1. Plasma levels of heparin binding protein (HBP, dark grey bars), lactoferrin (LF, light grey bars) 
and myeloperoxidase (MPO, white bars) in arterial samples during the study period. The levels are presented 
as fold-increase, i.e. as multiplies of respective baseline values. All parameters increased significantly (all 
p<0.001). HBP, LF and MPO all differed from each other before CPB, before reperfusion and after 
reperfusion (all p<0.001). 
 
Figure 2. Transcoronary differences (i.e. the difference between coronary sinus and artery) of neutrophil 
count as well as plasma concentrations of heparin binding protein (HBP), lactoferrin (LF, pre-ischemia 
missing) and myeloperoxidase (MPO) before CPB and 5 min after aortic declamping. **, p<0.01, coronary 
sinus vs. artery; ***, p<0.001, coronary sinus vs. artery. 
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List of abbreviations  
AVR aortic valve replacement 
CI cardiac index 
CPB cardiopulmonary bypass 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
HBP heparin binding protein 
hFABP heart-type fatty acid binding protein 
IQR interquartile range 
LF lactoferrin 
MAP mean arterial pressure 
MPO myeloperoxidase 
PCWP pulmonary capillary wedge pressure 
pO2 partial pressure of oxygen 
SO2 oxygen saturation 
TnT troponin T 
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